Tag: clay semenkovich

Semenkovich Lab and collaborators show the evolution of type 2 diabetes through APT1 deficiency 

On January 11, Semenkovich Lab and collaborators, had their research titled “Palmitoylation couples insulin hypersecretion with β cell failure in diabetes,” published in “Cell Metabolism.”  Hyperinsulinemia is known to often come before type 2 diabetes. In the study, they explain how acyl-protein thioesterase 1 (APT1) knockdown in nondiabetic islets causes insulin hypersecretion.  By using palmitoylation proteomics, their […]

Semenkovich publishes research on mechanisms to improve targeted atherosclerosis therapy 

On June 15, Clay F. Semenkovich, MD and collaborators had their research titled “Altered Peroxisome Proliferator-Activated Receptor Alpha Signaling in Variably Diseased Peripheral Arterial Segments,” published in “Frontiers in Cardiovascular Medicine.”  “Peripheral atherosclerosis that accumulates in the extracranial carotid and lower extremity arteries can lead to significant morbidity and mortality. However, atherosclerotic disease progression is […]